Back to Journals » OncoTargets and Therapy » Volume 10

The clinical significance of CXCL5 in non-small cell lung cancer

Authors Wu K, Yu S, Liu Q, Bai X, Zheng X, Wu K

Received 10 August 2017

Accepted for publication 17 October 2017

Published 21 November 2017 Volume 2017:10 Pages 5561—5573

DOI https://doi.org/10.2147/OTT.S148772

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Carlos Vigil Gonzales

Kongju Wu,1,* Shengnan Yu,2,* Qian Liu,2 Xianguang Bai,1 Xinhua Zheng,1 Kongming Wu2

1Medical School of Pingdingshan University, Pingdingshan, Henan, 2Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China

*These authors contributed equally to this work

Abstract: As a CXC-type chemokine, ENA78/CXCL5 is an important attractant for granulocytes by binding to its receptor CXCR2. Recent studies proved that CXCL5/CXCR2 axis plays an oncogenic role in many human cancers. However, the exact clinical significance of CXCL5 in lung cancer has not been well defined. Here, we found that the serum protein expression of CXCL5 was significantly increased in non-small cell lung cancer (NSCLC) compared with that in healthy volunteers. Immunohistochemistry staining revealed that CXCL5 protein was higher in various lung cancer tissues compared with normal tissues. Moreover, CXCL5 expression correlated with histological grade, tumor size, and TNM stage in NSCLC. Elevated CXCL5 protein abundance predicted poor overall survival in adenocarcinoma patients. Further meta-analysis demonstrated that CXCL5 mRNA expression was also positively associated with tumor stage, lymph node metastasis, and worse survival. Kaplan–Meier plot analyses indicated high CXCL5 was associated with short overall survival and progression-free survival. Together, these results indicated that CXCL5 may be a potential biomarker for NSCLC.

Keywords:
non-small cell lung cancer, chemokine, CXCL5, migration, prognosis
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis

Xu HX, Tian YJ, Yuan X, Liu Y, Wu H, Liu Q, Wu GS, Wu KM

OncoTargets and Therapy 2016, 9:431-444

Published Date: 21 January 2016

The role of CD44 in epithelial–mesenchymal transition and cancer development

Xu HX, Tian YJ, Yuan X, Wu H, Liu Q, Pestell RG, Wu KM

OncoTargets and Therapy 2015, 8:3783-3792

Published Date: 16 December 2015